Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410533 | 0.82 | TRPV1 (0.51) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL7407970 | 0.81 | MAPT (0.43) | NPSR1ALDH1A1GAAMAPTHPGD | |
| SCHEMBL7408515 | 0.76 | CHRM3 (0.36) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL23949707 | 0.75 | TMEM97 (0.57) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL13962551 | 0.75 | PTGDR2 (0.54) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL30422303 | 0.74 | DHFR (0.53) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL265902 | 0.74 | MEN1 (0.58) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL1456717 | 0.74 | MEN1 (0.66) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL27762585 | 0.74 | MEN1 (0.55) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL541411 | 0.73 | MEN1 (0.57) | MEN1KMT2ANPSR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250025448-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2025-01-23 | — | — | US | disclosed |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230051859-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | US | disclosed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | disclosed |
| US-11278529-B2 | Methods for treating aggression associated with Alzheimer's disease | OVID THERAPEUTICS INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220016091-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| EP-3151832-B1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795156-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ANGELMAN SYNDROME | Ovid Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-9446028-B2 | Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome | OVID THERAPEUTICS INC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160228418-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2016-08-11 | — | — | US | disclosed |
| US-9339495-B2 | Methods of increasing tonic inhibition and treating secondary insomnia | OVID THERAPEUTICS INC (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160038469-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150352085-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2015-12-10 | — | — | US | disclosed |
| WO-2015187851-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-0000338-B1 | ISOXAZOLO(5,4-C)PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | H.Lundbeck & Co., A/S (DK) | 1981-11-25 | — | — | EP | disclosed |
| US-4301287-A | FOR TREATMENT OF PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | H. LUNDBECK & CO. A/S (DK) | 1981-11-17 | — | — | US | disclosed |
| US-4278676-A | NERVOUS SYSTEM DISORDERS, CYCLIZATION, HYDROLYSIS | H. LUNDBECK & CO. A/S (DK) | 1981-07-14 | — | — | US | disclosed |
| EP-0000338-A2 | Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them | H.Lundbeck & Co., A/S (DK) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278529-B2 | Methods for treating aggression associated with Alzheimer's disease | SLC6A11, GABBR1, SLC6A1 | MEN1 3808/4885KMT2A 805/4885NPSR1 145/4885 |
| US-20250186429-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | MEN1 3664/4885KMT2A 1207/4885NPSR1 121/4885 |
| US-20150352085-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | MEN1 4384/4885KMT2A 199/4885NPSR1 445/4885 |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | MECP2, GABBR1, GABBR2 | MEN1 3664/4885KMT2A 1207/4885NPSR1 121/4885 |
| US-20250025448-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | MEN1 4384/4885KMT2A 199/4885NPSR1 445/4885 |
| US-20220016091-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | MEN1 4384/4885KMT2A 199/4885NPSR1 445/4885 |
| US-12201631-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | MECP2, GABBR1, GABBR2 | MEN1 3664/4885KMT2A 1207/4885NPSR1 121/4885 |
| US-20160038469-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | MEN1 4384/4885KMT2A 199/4885NPSR1 445/4885 |
| US-20230051859-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | MEN1 4384/4885KMT2A 199/4885NPSR1 445/4885 |
| US-20230031479-A1 | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MECP2, GABBR1, GABBR2 | MEN1 3664/4885KMT2A 1207/4885NPSR1 121/4885 |
| US-20160228418-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | MEN1 4384/4885KMT2A 199/4885NPSR1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.